SecBot SecBot
8-K ·Filed Jul 17, 2026

KPTI

Karyopharm Therapeutics Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed4mo ago SEC0001193125-26-307964
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a standard retention tool for a biotech approaching catalysts, no departure or appointment signal. Monitor upcoming catalyst readouts for the real stock-moving events; the retention program itself has no trading implications.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.47
T+0 close · Jul 17, 2026 · via day close
Latest settled
−94.28%
T+60 · $0.4274
Vs SPY
−99.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 20 $7.47entry
  2. T+1 · 4mo ago +5.29%α +4.45% · $7.87
  3. T+5 · 4mo ago −0.80%α −0.38% · $7.41
  4. T+20 · 3mo ago −75.77%α −79.89% · $1.81
  5. T+60 · 5w ago −94.28%α −99.12% · $0.4274
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Karyopharm Therapeutics implemented a 2026 Leadership Cash Retention Program providing lump-sum cash awards totaling $3.715 million to its CEO, CFO, and two other named executive officers. The program replaces the 2026 Annual Bonus Plan and is designed to retain key personnel through an upcoming catalyst period, with awards subject to clawback if employment terminates before 12 months (or 30 days post-change-of-control). This is a routine compensatory arrangement with no departure or appointment of officers, neutral for the stock.

Key Facts

  • CEO Richard Paulson receives $1,725,000 retention award
  • CFO Lori Macomber receives $625,000 retention award
  • Total retention awards to named executive officers: $3,715,000
  • Program replaces previously guaranteed 2026 Annual Bonus Plan amounts
  • Awards subject to clawback if employment ends before 12 months (or 30 days post-change-of-control) for reasons other than without-cause termination, good reason resignation, death, or permanent disability
  • Retention awards reduce amounts payable under existing severance arrangements

Financial Impact

$3.715 million in aggregate cash retention awards to four named executive officers

cash compensationseverance liabilities

Risk Factors

  • Retention awards may not prevent key departure if catalyst results are negative
  • Cash outlay of $3.715M reduces cash runway modestly

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-307964
Document: 0001193125-26-307964-index-headers.html0001193125-26-307964
Document: 0001193125-26-307964-index.html0001193125-26-307964
Document: 0001193125-26-307964.txt0001193125-26-307964

US Market Status

Market Closed · Opens in 7h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 17, 2026